Literature DB >> 10873765

Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes.

M H Skiadopoulos1, S R Surman, A P Durbin, P L Collins, B R Murphy.   

Abstract

Recombinant parainfluenza virus 3 (rPIV3) is being developed as a vector to express foreign genes as a bivalent or multivalent live attenuated virus vaccine. In the present study, we examined the effect of inserted foreign sequence on virus replication in vitro and in vivo, focusing on the parameter of insert length. In one type of construct, foreign sequence of increasing length was flanked by PIV3 transcription signals and inserted as an additional gene unit (GU insert) between the HN and L genes, so that one additional mRNA would be made. In a second type of construct, foreign sequence was inserted into the downstream NCR (NCR insert) of the HN gene, so that the number of encoded mRNAs remained unchanged. In each case, the foreign sequence was designed to lack any significant open reading frame, which permitted an evaluation of the effect of insert length on replication independent of an effect of an expressed protein. The GU or NCR insert sizes ranged from 168 nucleotides (nt) to 3918 nt. rPIV3s containing GU insertions of up to 3918 nt in length, the largest size tested, were viable and replicated efficiently at permissive temperatures in vitro, but a reduction in plaque size was seen at 39 degrees C and 40 degrees C. The rPIV3 with a 3918-nt GU insertion was restricted in replication in the upper (fivefold) and lower (25-fold) respiratory tracts of hamsters. Although a 1908-nt GU insertion did not significantly modify replication of wild-type PIV3 in vitro or in vivo, its introduction significantly augmented the level of temperature sensitivity (ts) and attenuation (att) specified by three mutations in the L protein of a cold-passaged attenuated PIV3 vaccine virus. rPIV3s bearing a 3126- or 3894-nt NCR insertion exhibited in vitro and in vivo phenotypes like those of the rPIV3s bearing similar-sized GU insertions. These findings indicate that rPIV3s whose genome length has been increased by more than 3000 nt by either a GU or an NCR insertion exhibit an unexpected host-range phenotype, that is, efficient replication in vitro but restricted replication in hamsters, especially in the lower respiratory tract. Furthermore, these effects were greatly enhanced when the rPIV3 backbone contained other ts or att mutations. The implications of these findings for the use of single-stranded, negative-sense RNA viruses as vectors for vaccines are discussed. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873765     DOI: 10.1006/viro.2000.0372

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  20 in total

Review 1.  Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.

Authors:  Brian R Murphy; Peter L Collins
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 2.  Nonsegmented negative-strand viruses as vaccine vectors.

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

3.  More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Josephine McAuliffe; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

4.  The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations.

Authors:  Mario H Skiadopoulos; Leatrice Vogel; Jeffrey M Riggs; Sonja R Surman; Peter L Collins; Brian R Murphy
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Attenuated acute liver injury in mice by naked hepatocyte growth factor gene transfer into skeletal muscle with electroporation.

Authors:  F Xue; T Takahara; Y Yata; M Minemura; C Y Morioka; S Takahara; E Yamato; K Dono; A Watanabe
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

6.  Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.

Authors:  A C Schmidt; J M McAuliffe; B R Murphy; P L Collins
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  α-Fetoprotein gene delivery to the nasal epithelium of nonhuman primates by human parainfluenza viral vectors.

Authors:  Liqun Zhang; Maria P Limberis; Catherine Thompson; Marcelo B Antunes; Cindy Luongo; James M Wilson; Peter L Collins; Raymond J Pickles
Journal:  Hum Gene Ther       Date:  2010-11-03       Impact factor: 5.695

8.  The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness.

Authors:  Mario H Skiadopoulos; Stéphane Biacchesi; Ursula J Buchholz; Jeffrey M Riggs; Sonja R Surman; Emerito Amaro-Carambot; Josephine M McAuliffe; William R Elkins; Marisa St Claire; Peter L Collins; Brian R Murphy
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  Live-attenuated respiratory syncytial virus vaccines.

Authors:  Ruth A Karron; Ursula J Buchholz; Peter L Collins
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

10.  CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium.

Authors:  Liqun Zhang; Brian Button; Sherif E Gabriel; Susan Burkett; Yu Yan; Mario H Skiadopoulos; Yan Li Dang; Leatrice N Vogel; Tristan McKay; April Mengos; Richard C Boucher; Peter L Collins; Raymond J Pickles
Journal:  PLoS Biol       Date:  2009-07-21       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.